Christopher P Cannon Selected Research

Glucose (Dextrose)

1/2023	Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study.
1/2023	Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium-glucose cotransporter-2 inhibitor ertugliflozin.
1/2022	The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV.
1/2022	Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial.
1/2021	Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized Trial.
11/2020	The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program.
12/2018	Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV).
1/2018	Metabolic syndrome and the risk of adverse cardiovascular events after an acute coronary syndrome.
3/2010	Distribution of traditional and novel risk factors and their relation to subsequent cardiovascular events in patients with acute coronary syndromes (from the PROVE IT-TIMI 22 trial).
12/2008	Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Christopher P Cannon Research Topics

Disease

238	Acute Coronary Syndrome 01/2023 - 02/2002
229	Myocardial Infarction 03/2024 - 03/2002
98	Stroke (Strokes) 03/2024 - 07/2003
86	Hemorrhage 01/2022 - 12/2002
83	Heart Failure 11/2023 - 03/2002
78	Cardiovascular Diseases (Cardiovascular Disease) 03/2024 - 04/2002
72	Type 2 Diabetes Mellitus (MODY) 04/2024 - 12/2007
72	ST Elevation Myocardial Infarction 08/2021 - 03/2002
54	Unstable Angina 08/2018 - 10/2002
53	Atrial Fibrillation 01/2023 - 09/2004
50	Thrombosis (Thrombus) 07/2022 - 07/2002
46	Coronary Artery Disease (Coronary Atherosclerosis) 01/2023 - 11/2002
42	Infections 01/2021 - 04/2002
38	Coronary Disease (Coronary Heart Disease) 01/2020 - 02/2003
31	Non-ST Elevated Myocardial Infarction 01/2017 - 10/2002
24	Hypertension (High Blood Pressure) 01/2023 - 02/2003
22	Chronic Renal Insufficiency 04/2024 - 01/2010
20	Inflammation (Inflammations) 01/2023 - 02/2003
20	Diabetes Mellitus 01/2022 - 10/2002
18	Infarction (Infarctions) 08/2009 - 04/2002
16	Ischemic Stroke 10/2022 - 09/2004
15	Neoplasms (Cancer) 07/2022 - 12/2003
15	Atherosclerosis 01/2020 - 02/2003
12	Renal Insufficiency (Renal Failure) 01/2023 - 02/2003
12	Dyslipidemias (Dyslipidemia) 12/2022 - 11/2007
12	Albuminuria 11/2022 - 10/2010
12	Atherosclerotic Plaque (Atheroma) 12/2021 - 06/2004
11	Peripheral Arterial Disease 01/2022 - 08/2004
11	Ischemia 01/2014 - 06/2002
10	Kidney Diseases (Kidney Disease) 11/2023 - 12/2017
10	Hypercholesterolemia 01/2022 - 04/2003
10	Left Ventricular Dysfunction 05/2017 - 01/2003
9	Obesity 12/2019 - 03/2006
7	Body Weight (Weight, Body) 01/2022 - 03/2005
7	Vascular Diseases (Vascular Disease) 01/2017 - 04/2003
7	Arthritis (Polyarthritis) 12/2012 - 08/2006
7	Osteoarthritis 06/2011 - 08/2006

Drug/Important Bio-Agent (IBA)

100	Clopidogrel (Plavix)FDA Link 08/2021 - 10/2002
87	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2023 - 04/2004
69	LipidsIBA 01/2023 - 04/2003
64	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 12/2021 - 09/2002
55	TicagrelorIBA 10/2023 - 11/2007
46	Atorvastatin (Lipitor)FDA Link 01/2018 - 04/2002
43	LDL CholesterolIBA 01/2023 - 10/2004
43	Pravastatin (Pravachol)FDA LinkGeneric 01/2018 - 04/2002
42	Biomarkers (Surrogate Marker)IBA 01/2023 - 04/2002
37	oxidized low density lipoproteinIBA 01/2023 - 12/2003
32	Tirofiban (Aggrastat)FDA Link 11/2020 - 07/2002
32	C-Reactive ProteinIBA 12/2018 - 04/2002
27	Ezetimibe (Zetia)FDA Link 01/2023 - 08/2014
24	omega-Chloroacetophenone (Mace)IBA 03/2024 - 12/2009
23	Simvastatin (Zocor)FDA LinkGeneric 10/2021 - 12/2005
21	CanagliflozinIBA 01/2023 - 12/2017
21	Warfarin (Coumadin)FDA LinkGeneric 12/2021 - 01/2009
20	CreatinineIBA 01/2023 - 10/2003
20	Dabigatran FDA Link 01/2022 - 11/2010
19	AnticoagulantsIBA 01/2023 - 12/2007
19	darapladibIBA 12/2021 - 10/2010
19	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2020 - 02/2002
16	ertugliflozinIBA 10/2023 - 12/2018
15	alogliptinIBA 01/2020 - 10/2011
15	Glycoproteins (Glycoprotein)IBA 07/2016 - 12/2002
15	Heparin (Liquaemin)FDA LinkGeneric 01/2011 - 09/2002
14	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2023 - 06/2004
14	Glucose (Dextrose)FDA LinkGeneric 01/2023 - 06/2006
14	TroponinIBA 09/2017 - 07/2002
13	Simvastatin Drug Combination Ezetimibe (Vytorin)FDA Link 10/2021 - 11/2008
12	HDL CholesterolIBA 07/2022 - 01/2007
12	orbofibanIBA 10/2006 - 12/2002
11	Sodium-Glucose Transporter 2 InhibitorsIBA 11/2023 - 01/2019
10	Sodium-Glucose Transport ProteinsIBA 04/2024 - 01/2019
10	pro-brain natriuretic peptide (1-76)IBA 01/2021 - 04/2008
10	Troponin IIBA 01/2018 - 04/2002
9	Growth Differentiation Factor 15IBA 01/2023 - 01/2011
9	Angiotensin Receptor AntagonistsIBA 01/2023 - 06/2009
9	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA 01/2022 - 02/2014
9	alirocumabIBA 09/2020 - 06/2015
9	EtoricoxibIBA 12/2012 - 08/2006
9	N(2)-(3-trifluoromethylphenyl)guanineIBA 05/2008 - 04/2002
8	Troponin T (Troponin T1)IBA 12/2022 - 07/2002
8	Vitamin K FDA Link 01/2021 - 10/2017
8	1-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)IBA 01/2018 - 04/2006
8	Diclofenac (SR 38)FDA LinkGeneric 12/2012 - 08/2006
7	CholesterolIBA 01/2023 - 12/2004
7	SodiumIBA 01/2023 - 12/2018
7	Triglycerides (Triacylglycerol)IBA 09/2015 - 01/2007
7	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2014 - 08/2006
7	RimonabantIBA 04/2008 - 03/2006
7	Platelet Membrane Glycoprotein IIbIBA 03/2008 - 10/2002
6	(2S,3R,4R,5S,6R)- 2- (4- chloro- 3- (4- ethoxybenzyl)phenyl)- 6- (methylthio)tetrahydro- 2H- pyran- 3,4,5- triolIBA 04/2024 - 01/2021
6	Hemoglobins (Hemoglobin)IBA 11/2023 - 11/2008
6	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 07/2023 - 12/2016

Therapy/Procedure

282	Therapeutics 01/2024 - 03/2002
71	Percutaneous Coronary Intervention 07/2022 - 04/2002
30	Stents 07/2022 - 05/2006
27	Thrombolytic Therapy 08/2009 - 10/2002
26	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 01/2019 - 12/2002
24	Patient Readmission 01/2017 - 09/2002
22	Secondary Prevention 01/2023 - 02/2004
8	Conservative Treatment 09/2017 - 07/2002